H
Overview
Henry Meds provides weight loss programs delivered through telehealth. Patients meet with licensed healthcare providers via a HIPAA-compliant platform to review medical history and receive a personalized treatment plan with included medication. The service avoids injections, long-term contracts, and in-person office visits, offering transparent pricing and easy access. The goal is to make effective weight loss convenient and affordable for a broad audience by combining remote care with medication.
Work here?Claim your company
Simplify's take
What believers are saying
- Henry Meds launched compounded oral tirzepatide tablets on November 2, 2026.
- Its November 9, 2026 landing page advertises tirzepatide at $147 monthly.
- Broad telehealth weight-loss offerings support cross-sell into oral, injectable, and hormone programs.
What critics are saying
- Eli Lilly's April 2025 lawsuit targets Henry Meds' personalized tirzepatide claims.
- Judge Beeler ordered more discovery on October 14, 2026; facts close December 4.
- FDA's April 30, 2026 proposal threatens compounded semaglutide, tirzepatide, and liraglutide supplies.
What makes Henry Meds unique
- Henry Meds sells compounded oral tirzepatide tablets, updated November 2026.
- It pairs online visits with transparent cash pricing and no insurance requirement.
- Its menu spans oral semaglutide, tirzepatide, liraglutide, phentermine, and testosterone.
Help us improve and share your feedback! Did you find this helpful?